Novo Nordisk A/S (NYSE:NVO) went up by 0.52% from its latest closing price compared to the recent 1-year high of $122.16. The company’s stock price has collected -7.48% of loss in the last five trading sessions. Barron’s reported on 11/18/21 that Dicerna Stock Skyrockets as Novo Nordisk to Buy Research Partner for $3.3 Billion
Is It Worth Investing in Novo Nordisk A/S (NYSE :NVO) Right Now?
Novo Nordisk A/S (NYSE:NVO) scored a price-to-earnings ratio above its average ratio, recording 34.34 x from its present earnings ratio. Plus, the 36-month beta value for NVO is at 0.47. Opinions of the stock are interesting as 11 analysts out of 30 who provided ratings for Novo Nordisk A/S declared the stock was a “buy,” while 2 rated the stock as “overweight,” 13 rated it as “hold,” and 4 as “sell.”
The average price from analysts is $113.40, which is $27.95 above the current price. NVO currently public float of 1.11B and currently shorts hold a 0.16% ratio of that float. Today, the average trading volume of NVO was 1.44M shares.
NVO’s Market Performance
NVO stocks went down by -7.48% for the week, with a monthly drop of -11.12% and a quarterly performance of 0.28%, while its annual performance rate touched 32.27%. The volatility ratio for the week stands at 2.62% while the volatility levels for the past 30 days are set at 2.28% for Novo Nordisk A/S. The simple moving average for the period of the last 20 days is -7.11% for NVO stocks with a simple moving average of -1.08% for the last 200 days.
Analysts’ Opinion of NVO
Many brokerage firms have already submitted their reports for NVO stocks, with Cowen repeating the rating for NVO by listing it as a “Outperform.” The predicted price for NVO in the upcoming period, according to Cowen is $130 based on the research report published on April 25th of the current year 2022.
NVO Trading at -5.67% from the 50-Day Moving Average
After a stumble in the market that brought NVO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -14.58% of loss for the given period.
Volatility was left at 2.28%, however, over the last 30 days, the volatility rate increased by 2.62%, as shares sank -12.22% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -0.31% lower at present.
During the last 5 trading sessions, NVO fell by -7.48%, which changed the moving average for the period of 200-days by +14.06% in comparison to the 20-day moving average, which settled at $111.61. In addition, Novo Nordisk A/S saw -6.83% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for NVO
Current profitability levels for the company are sitting at:
- +41.91 for the present operating margin
- +82.04 for the gross margin
The net margin for Novo Nordisk A/S stands at +33.92. The total capital return value is set at 68.98, while invested capital returns managed to touch 63.71. Equity return is now at value 73.40, with 27.30 for asset returns.
Based on Novo Nordisk A/S (NVO), the company’s capital structure generated 37.66 points at debt to equity in total, while total debt to capital is 27.36. Total debt to assets is 13.70, with long-term debt to equity ratio resting at 18.32. Finally, the long-term debt to capital ratio is 13.31.
When we switch over and look at the enterprise to sales, we see a ratio of 11.33, with the company’s debt to enterprise value settled at 0.02. The receivables turnover for the company is 4.04 and the total asset turnover is 0.83. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.86.